Stock Price for Checkpoint Therapeutics Inc. (CKPT) on Nasdaq: $1.80

Checkpoint Therapeutics Inc. (CKPT) is a clinical-stage biopharmaceutical company that focuses on developing innovative treatments for patients with solid tumor cancers. With a diverse product portfolio that includes drugs like CK-301, CK-101, CK-103, CK-302, and Anti-CAIX, Checkpoint Therapeutics aims to cater to the growing demand for effective cancer therapies. As of December 20, 2023, the stock price for Checkpoint Therapeutics Inc. (CKPT) on Nasdaq stands at $1.80. However, investors should note that the stock has displayed considerable volatility, with a 52-week range of $1.30 to $8.15. Despite this, Checkpoint Therapeutics Inc. maintains a market cap of $41.17 million and boasts 22.83 million shares outstanding.

▶ [Kucoin] Transaction fee 0% discount CODE◀

Company Overview

Background

Checkpoint Therapeutics Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing innovative treatments for patients with solid tumor cancers. The company is focused on addressing the unmet medical needs in this area and has a strong commitment to improving patient outcomes.

Product Portfolio

Checkpoint Therapeutics Inc. has developed a diverse product portfolio that consists of several promising drug candidates. These drugs aim to target specific mechanisms of solid tumor cancers and provide more effective treatment options for patients.

▶ [Kucoin] Transaction fee 0% discount CODE◀

Stock Price Performance

Current Stock Price

As of December 20, 2023, the stock price for Checkpoint Therapeutics Inc. (CKPT) on Nasdaq is $1.80. This represents the current market value of the company’s shares and reflects investor sentiment towards the company’s prospects.

Previous Stock Performance

Checkpoint Therapeutics Inc.’s stock has experienced significant volatility in the market. Over the past year, the stock price has ranged from a low of $1.30 to a high of $8.15. This fluctuation indicates the uncertainty surrounding the company’s performance and the potential for both gains and losses for investors.

52-Week Range

The 52-week range of Checkpoint Therapeutics Inc.’s stock price demonstrates the extent of price movement over the past year. Investors should consider this range when evaluating the stock’s performance and potential for growth. The range for CKPT is $1.30 to $8.15.

Market Capitalization and Share Structure

Market Capitalization

Checkpoint Therapeutics Inc. currently has a market capitalization of $41.17 million. This figure represents the total value of the company’s outstanding shares in the market. Market capitalization is an important metric for investors as it provides an indication of the company’s size and overall worth.

Outstanding Shares

Checkpoint Therapeutics Inc. has 22.83 million outstanding shares. These shares represent the ownership stake held by investors in the company. The number of outstanding shares is a key factor in determining a company’s market capitalization and can influence the stock’s price and liquidity.

Clinical-Stage Biopharmaceutical Company

Specialization

As a clinical-stage biopharmaceutical company, Checkpoint Therapeutics Inc. specializes in the development of novel treatments for patients with solid tumor cancers. The company’s expertise lies in identifying and targeting specific mechanisms within these types of cancers to develop more effective and targeted therapies.

Solid Tumor Cancer Treatments

Checkpoint Therapeutics Inc.’s product portfolio is focused on addressing the unique challenges posed by solid tumor cancers. These types of cancers can be difficult to treat due to their resistance to traditional therapies. The company’s research and development efforts aim to overcome these challenges and provide innovative treatment options for patients.

Product Portfolio

CK-301

One of the key drug candidates in Checkpoint Therapeutics Inc.’s product portfolio is CK-301. This drug is being developed as a potential treatment for patients with solid tumor cancers. It targets specific mechanisms within these cancers to inhibit their growth and progression.

CK-101

Another important drug candidate is CK-101, which is designed to address the unmet medical needs of patients with solid tumor cancers. This drug aims to disrupt the signaling pathways in these cancers and potentially improve patient outcomes.

CK-103

Checkpoint Therapeutics Inc. is also developing CK-103 as a potential treatment option for solid tumor cancers. This drug targets specific mechanisms within these cancers to inhibit their growth and spread, with the goal of providing patients with more effective treatment options.

CK-302

CK-302 is another drug candidate in Checkpoint Therapeutics Inc.’s product portfolio. It is being developed to target certain mechanisms within solid tumor cancers and potentially provide patients with a novel treatment option that may improve outcomes.

Anti-CAIX

Finally, Checkpoint Therapeutics Inc. has developed Anti-CAIX, a drug candidate that focuses on a specific target within solid tumor cancers. This drug aims to disrupt the cancer’s ability to grow and spread, potentially improving patient prognosis.

Current Stock Price

Price on Nasdaq

The current stock price for Checkpoint Therapeutics Inc. (CKPT) on Nasdaq is $1.80 as of December 20, 2023. This represents the market value of the company’s shares and reflects investor sentiment towards the company’s prospects.

Date of Pricing

The stock price of $1.80 on Nasdaq is based on the market’s evaluation of Checkpoint Therapeutics Inc. as of December 20, 2023. Investors should consider this date when analyzing the stock’s performance and making investment decisions.

Outstanding Shares

Definition

Outstanding shares refer to the total number of shares of a company’s stock that are currently held by investors. These shares represent the ownership stake in the company and can fluctuate over time due to factors such as stock issuances or repurchases.

Number of Shares for Checkpoint Therapeutics Inc.

Checkpoint Therapeutics Inc. currently has 22.83 million outstanding shares. This figure represents the ownership stake held by investors in the company. The number of outstanding shares is an important metric for investors to consider when evaluating a company’s market capitalization and potential for growth.

In conclusion, Checkpoint Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel treatments for patients with solid tumor cancers. With a diverse product portfolio that includes drug candidates such as CK-301, CK-101, CK-103, CK-302, and Anti-CAIX, the company is committed to providing innovative treatment options to address the unmet medical needs in this field. While the stock price has experienced volatility, with a 52-week range of $1.30 to $8.15, the current stock price on Nasdaq is $1.80 as of December 20, 2023. With a market capitalization of $41.17 million and 22.83 million outstanding shares, Checkpoint Therapeutics Inc. continues to focus on advancing its clinical pipeline and making a significant impact in the field of solid tumor cancer treatments.

▶ [Kucoin] Transaction fee 0% discount CODE◀